fda glp-1 warning letters news May 18, 2026: warns 503B compounding pharmacy for producing tirzepatide after shortage ended – Partnership for Safe Medicines 3/7/26 The FDA just warned
Description
Some studies suggest that individuals with obesity may have alterations in GLP-1 signaling, though findings are heterogeneous
2024;11 doi: 10.1016/j.obpill.2024.100121
Article 1601602
Our guide on combining metformin with GLP-1 medications discusses managing overlapping side effects
122, no
Glucagon-like Peptide-1 Receptor Agonists and Risk of Substance Use Disorders among US Veterans with Type 2 Diabetes: Cohort Study. BMJ , vol
